Hospital Profile
Name | Jefferson Community Health & Life |
---|
Type | Critical Access Hospital |
---|
Location | P O Box 277, 2200 H St, Fairbury, Nebraska |
---|
Ownership | Voluntary non-profit - Private |
---|
Emergency Services | Yes |
---|
Medicare ID (CCN) | 281319 |
Patients' Experience Survey:
Willingness to Recommend Hospital:
Yes Patients who reported YES, they would definitely recommend the hospital
Probably Patients who reported YES, they would probably recommend the hospital
No Patients who reported NO, they would probably not or definitely not recommend the hospital
Cleanliness of Hospital Environment:
Always Patients who reported that their room and bathroom were "Always" clean
Usually Patients who reported that their room and bathroom were "Usually" clean
Sometimes or Never Patients who reported that their room and bathroom were "Sometimes" or "Never" clean
Quietness of Hospital Environment:
Always Patients who reported that the area around their room was "Always" quiet at night
Usually Patients who reported that the area around their room was "Usually" quiet at night
Sometimes or Never Patients who reported that the area around their room was "Sometimes" or "Never" quiet at night
Always Patients who reported that their nurses "Always" communicated well
Usually Patients who reported that their nurses "Usually" communicated well
Sometimes or Never Patients who reported that their nurses "Sometimes" or "Never" communicated well
Always Patients who reported that their doctors "Always" communicated well
Usually Patients who reported that their doctors "Usually" communicated well
Sometimes or Never Patients who reported that their doctors "Sometimes" or "Never" communicated well
Responsiveness of Hospital Staff:
Always Patients who reported that they "Always" received help as soon as they wanted
Usually Patients who reported that they "Usually" received help as soon as they wanted
Sometimes or Never Patients who reported that they "Sometimes" or "Never" received help as soon as they wanted
Communication about Medicines:
Always Patients who reported that staff "Always" explained about medicines before giving it to them
Usually Patients who reported that staff "Usually" explained about medicines before giving it to them
Sometimes or Never Patients who reported that staff "Sometimes" or "Never" explained about medicines before giving it to them
Yes Patients who reported that YES, they were given information about what to do during their recovery at home
No Patients who reported that NO, they were not given information about what to do during their recovery at home
Always Patients who "Strongly Agree" they understood their care when they left the hospital
Usually Patients who “Agree” they understood their care when they left the hospital
Sometimes or Never Patients who “Disagree” or “Strongly Disagree” they understood their care when they left the hospital
NPI Associated with the Hospital:
Unlike individual providers, Hospitals may have multiple NPI numbers for example, there can be a separate NPI for each unit within the hospital. We have found possible NPI number/s associated with Jefferson Community Health & Life from NPPES records by matching pattern on the basis of name, address, phone number etc. Please use this information accordingly.
NPI Number | 1477660397 |
Organization Name | JEFFERSON COMMUNITY HEALTH CENTER, INC. |
Doing Business As | JEFFERSON COMMUNITY HEALTH CENTER |
Address | 2200 H St, Box 277, Fairbury, NE 68352 |
Hospital Type | General Acute Care Hospital - Critical Access |
Phone Number | 402-729-3351 |
News Archive
Patient dosing in CyDex Pharmaceuticals' Phase 2A clinical trial of CDX-353 initiated
CyDex Pharmaceuticals, Inc. today announced the initiation of patient dosing in the company's Phase 2A clinical trial of its Captisol-Enabled® Melphalan HCL. Melphalan is an FDA-approved chemotherapy for the palliative treatment of multiple myeloma marketed under the brand name Alkeran® by GlaxoSmithKline.
Campaign launched to tackle childhood obesity
Urging children to get at least 60 minutes of physical activity each day, Pennsylvania Health Secretary Everette James and Education Secretary Gerald Zahorchak today helped to kick off the NFL Play 60 national youth health and fitness campaign.
New denosumab Phase III trial data in high-risk prostate cancer presented at AUA conference
Data on the use of denosumab (Xgeva) to improve bone metastases-free survival in men with high-risk prostate cancer was presented at the American Urological Association conference today for the first time.
HealthPartners programs reduce medical expenses by more than $137 million
HealthPartners programs designed to improve the quality and efficiency of care reduced medical expenses by more than $137 million last year, according to the organization's 2009 Return on Investment report.
New blood clotting analysis system could help determine effects antithrombotic (anti-clotting) drugs
A new blood clotting analysis system designed in Japan makes it easier to determine the effects of taking one or more antithrombotic (anti-clotting) drugs.
Read more Medical News
› Verified 9 days ago
Structural Quality Measures:
Able to receive lab results electronically | Not Available |
Able to track patients' lab results, tests, and referrals electronically between visits | Not Available |
News Archive
Patient dosing in CyDex Pharmaceuticals' Phase 2A clinical trial of CDX-353 initiated
CyDex Pharmaceuticals, Inc. today announced the initiation of patient dosing in the company's Phase 2A clinical trial of its Captisol-Enabled® Melphalan HCL. Melphalan is an FDA-approved chemotherapy for the palliative treatment of multiple myeloma marketed under the brand name Alkeran® by GlaxoSmithKline.
Campaign launched to tackle childhood obesity
Urging children to get at least 60 minutes of physical activity each day, Pennsylvania Health Secretary Everette James and Education Secretary Gerald Zahorchak today helped to kick off the NFL Play 60 national youth health and fitness campaign.
New denosumab Phase III trial data in high-risk prostate cancer presented at AUA conference
Data on the use of denosumab (Xgeva) to improve bone metastases-free survival in men with high-risk prostate cancer was presented at the American Urological Association conference today for the first time.
HealthPartners programs reduce medical expenses by more than $137 million
HealthPartners programs designed to improve the quality and efficiency of care reduced medical expenses by more than $137 million last year, according to the organization's 2009 Return on Investment report.
New blood clotting analysis system could help determine effects antithrombotic (anti-clotting) drugs
A new blood clotting analysis system designed in Japan makes it easier to determine the effects of taking one or more antithrombotic (anti-clotting) drugs.
Read more News
› Verified 9 days ago